

PCRS Position Statement



Triple therapy in COPD

August 2023

PCRS advocate a pragmatic approach to the pharmacological management of patients with COPD guided by the predominance of breathlessness and/or exacerbations and the presence or absence of comorbid asthma. Clinicians must undertake a holistic evaluation for alternative causes of persistent daily symptoms or repeated exacerbations and consider seeking advice from a respiratory specialist before escalating to triple therapy (a respiratory specialist may be a GP/nurse/consultant).

Primary Care Respiratory Society 483 Green Lanes, London, N13 4BS
Registered Charity 1098117 Company No 4298947 VAT Registration Number 866 1543 09
Telephone +44 (0)1675 477600 Email info@pcrs-uk.org Website <http://www.pcrs-uk.org>

The Primary Care Respiratory Society is grateful to its corporate supporters including AstraZeneca UK Ltd, Chiesi Ltd and Lupin Healthcare Limited, for their financial support which supports the core activities of the Charity and allows PCRS to make its services either freely available or at greatly reduced rates to its members.

Background

Triple therapy for patients with chronic obstructive pulmonary disease (COPD) refers to the combination of long-acting muscarinic antagonists (LAMA), long-acting beta2 agonists (LABA) and inhaled corticosteroids (ICS). Given the small but increased risk of pneumonia for patients prescribed ICS as part of a triple therapy regimen, it is essential that such treatment is only prescribed for patients likely to derive a clinical benefit.

Current guidance from NICE issued in 2019 advises that for patients with COPD and persistent symptoms on dual therapy (LAMA+LABA or LABA+ICS) a clinical review is conducted prior to initiating triple therapy to ensure pharmacological and non-pharmacological management is optimised and tobacco dependence has been addressed.¹ The review should also evaluate whether the acute episodes of worsening symptoms and any impact of day-to-day symptoms on quality of life are due to COPD and not caused by another physical or mental health condition or due to environmental/social factors such as poor living conditions.

Triple therapy can be considered for patients whose day-to-day symptoms are adversely impacting their quality of life OR have had a severe exacerbation requiring hospitalisation OR have had 2 moderate exacerbations within the previous 12 months. For patients taking LABA+LAMA whose day-to-day symptoms are adversely impacting their quality of life, a 3-month trial of triple therapy may be considered; if no improvement in symptoms (clinician assessment) or reduction in exacerbation frequency is achieved then patients should be switched back to LABA+LAMA. GOLD guidelines advocate that treatment should be guided by predominant breathlessness or exacerbations and that ICS therapy should be considered only as part of a triple therapy regimen and for patients with persistent symptoms and co-existing features of asthma or a raised eosinophil count (>300 cells/mL) while not receiving steroid treatment.²

PCRS position

- PCRS advocate a pragmatic approach to the pharmacological management of patients with COPD guided by the predominance of breathlessness and/or exacerbations and the presence or absence of comorbid asthma.^{3,4}
 - Triple therapy should usually be reserved for patients with persistent daily symptoms or repeated exacerbations despite optimal dual therapy after a careful review of potential alternative causes.
 - Triple therapy is not generally beneficial for patients with COPD with predominant breathlessness without asthma, with no severe exacerbations, or fewer than 2 exacerbations in the last year.
 - Consider a single inhaler triple therapy device to improve adherence, reduce inhaler technique errors and reduce inhaler burden.
- Clinicians must undertake a holistic evaluation for alternative causes of persistent daily symptoms or repeated exacerbations which should include:
 - Review of diagnosis
 - Optimisation of pharmacological therapy (inhaler technique, adherence)
 - Optimisation of nonpharmacological therapy including pulmonary rehabilitation and vaccinations
 - Smoking cessation/tobacco dependence assessment
 - Co-morbidities
 - Any potential environmental/social factors (e.g. poor living conditions)
- If after holistic evaluation and treatment optimisation, daily symptoms or repeated exacerbations persist, clinicians should consider seeking advice from a respiratory specialist before escalating to triple therapy (a respiratory specialist may be a GP/nurse/consultant).

References

1. <https://www.nice.org.uk/guidance/ng115>. Accessed August 2023.
2. <https://goldcopd.org/2023-gold-report-2/>. Accessed August 2023.
3. <https://www.pcrs-uk.org/resource/pcrs-consensus-guide-managing-copd>. Accessed August 2023.
4. <https://www.pcrs-uk.org/resource/gold-2023-implications-primary-care-patients-copd-uk>. Accessed August 2023.

Approved by the PCRS Executive policy lead on 14th August 2023